Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-172 in hyperphosphatemia patients on hemodialysis
NCT06745518Phase 2Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperphosphatemia comparing TS-172 with Placebo (2 arms). Primary endpoint: Achievement rate of the target serum phosphorus level at Week 8. Started Jan 2025; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT06745518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745518.